ライフサイエンスコーパス: neurotensin

1 ounts from the dorsomedial SCN (vasopressin, neurotensin).

2 a high charge state (e.g., triply protonated neurotensin).

3 rotonated neurotensin, and triply protonated neurotensin.

4 Met- and Leu-enkephalin, angiotensin I, and neurotensin.

5 re not detected including neuropeptide Y and neurotensin.

6 ides: [Lsy(8)] vasopressin, substance P, and neurotensin.

7 binding in the presence of excess unlabeled neurotensin.

8 f of the neuropeptide Y cells do not contain neurotensin.

9 erminal side of proline, for substance P and neurotensin.

10 to show a normal antinociceptive response to neurotensin.

11 izing mutations bound to the peptide agonist neurotensin.

12 ive oil-induced secretion of GLP-1, PYY, and neurotensin.

13 rosine kinases and required local release of neurotensin.

14 ith wakefulness such as orexin, histamine or neurotensin.

15 rats, virally mediated overexpression of the neurotensin 1 (NT1) receptor in the nucleus accumbens an

16 omotes inflammation and colon cancer via the neurotensin-1 receptor (NTR1).

17 In addition, we also tested PD149163, a neurotensin-1 receptor agonist, which has been shown to

18 to endocytic vesicles with agonist-activated neurotensin-1 receptor, oxytocin receptor, angiotensin I

19 -[2-(4-(18)F-fluorobenzamido)ethyl]maleimide-neurotensin ((18)F-FBEM-NT).

20 ide) or a VIP receptor antagonist (hybrid of neurotensin 6-11 and VIP 7-28).

21 NT69L, is a novel neurotensin (8-13) analog that participates in the modul

22 NT69L is a novel neurotensin (8-13) analog that produces atypical antipsy

23 A series of neurotensin(8-13) (NT) analogues were synthesized throug

24 Neurotensin(8-13) and two related analogues were used as

25 NT69L, an analog of neurotensin(8-13), acts like an atypical antipsychotic d

26 ng peptide receptor ligands (angiotensin II, neurotensin(8-13), an analogue of the C-terminal pentape

27 s; namely, [Tyr(1)]-leu-enkephalin, [Tyr(4)]-neurotensin(8-13), and [Tyr(3)]-octreotide, each of whic

28 A set of neurotensin[8-13] (NT[8-13]) analogues featuring substit

29 le hydrogens, whereas the +1 charge state of neurotensin (9-13) has 12 exchangeable hydrogens.

30 The b 2 portion of neurotensin (9-13) has 6 exchangeable hydrogens, whereas

31 sing a commercially available small peptide, neurotensin (9-13; RPYIL).

32 ize different positions on others, including neurotensin, a 13-residue peptide involved in modulation

33 Neurotensin, a neuropeptide growth factor, and its two s

34 Neurotensin, a tridecapeptide, is widely distributed in

35 The findings also support a volume mode of neurotensin actions, specifically affecting excitatory t

36 tral tegmental area neurons, substance P and neurotensin activate a channel complex containing NALCN

37 Neurotensin activated Akt in HCT-116 cells; this effect

38 Neurotensin activated AKT through miR-155-mediated suppr

39 eurons and that it may be useful to consider neurotensin agonists as an adjunct in the treatment of s

40 We tested the effect of a novel neurotensin analog (NT69L), injected intra-peritoneally

41 he study was to induce mild hypothermia with neurotensin analog NT77 or external cooling in a rat mod

42 NT69L is a neurotensin analog that can be administered peripherally

43 NT69L, a neurotensin analog that crosses the blood-brain barrier,

44 We report on a novel neurotensin analog with higher selectivity to NTS2, name

45 These results suggest that PIH induced by neurotensin analogs represented by ABS-201 are promising

46 we showed that one of our brain-penetrating neurotensin analogs, NT69L, blocks nicotine-induced loco

47 We induced regulated hypothermia with a neurotensin analogue (NT77) to determine whether it coul

48 onnatural amino acid was incorporated into a neurotensin analogue using standard Fmoc-based protocols

49 s, since it was present in 76% of cells with neurotensin and 45% of those with somatostatin, but only

50 the catabolism of bioactive peptides such as neurotensin and bradykinin.

51 gonadotropin-releasing hormone antagonists, neurotensin and complement C5a modulators, melanocortin-

52 up-regulated in carcinoid tumors, including neurotensin and connective tissue growth factor.

53 rginine ethyl ester (BAEE) and two peptides, neurotensin and insulin chain B.

54 Intermolecular cross-linking of neurotensin and intramolecular cross-linking of cytochro

55 levels of the dopaminergic circuit modulator neurotensin and is a member of a fold group that include

56 Here we show that neurotensin and its receptor are elevated in the rat col

57 This study points out that neurotensin and its two specific receptors are expressed

58 (ACE) can cleave angiotensin I, bradykinin, neurotensin and many other peptide substrates in vitro.

59 endogenous neuropeptide is highly related to neurotensin and neuromedin U, which are involved in bloo

60 Another NTSR, sortilin, which is common to neurotensin and neurotrophins, was also detected as we h

61 siological (GnRH, GnRH(1-9), bradykinin, and neurotensin) and fluorimetric (MCA-PLGPDL-Dnp and orthoa

62 nt elevation of c-fos, prolonged increase of neurotensin, and early reduction followed by recovery of

63 paB-alpha (IkappaB-alpha) levels; and c-fos, neurotensin, and ferritin H expression were determined b

64 l gut-brain peptides, including substance P, neurotensin, and galanin, emerged as important mediators

65 anorectic (appetite-suppressing: alpha-MSH, neurotensin, and GLP-1) peptides after intracerebroventr

66 Activation of orexin, neurotensin, and metabotropic glutamate Gq/11-linked rec

67 n 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potenti

68 gulators such as atrial natriuretic peptide, neurotensin, and orexin B are also discussed.

69 y protonated gramicidin S, doubly protonated neurotensin, and triply protonated neurotensin.

70 ubstance P, corticotropin-releasing hormone, neurotensin, and vasoactive intestinal peptide; small mo

71 othesis tested was that these two actions of neurotensin are mediated via its high-affinity receptor.

72 dulators, gamma-aminobutyric acid (GABA) and neurotensin, are shown to be present in IGL neurons.

73 We found that LHA MC4R-GFP neurons coexpress neurotensin as well as the leptin receptor but do not co

74 se include peptides, such as substance P and neurotensin, as well as acetylcholine and noradrenaline.

75 bradykinin specifically at Phe(5)-Ser(6) and neurotensin at Arg(8)-Arg(9).

76 n residues are at all four positions cleaves neurotensin at the neurolysin site, and the reverse muta

77 s increase neurotensin release from dopamine-neurotensin axons in the PFC.

78 A model for differential recognition of neurotensin based on differences in surface charge distr

79 mately 1; at higher receptor concentrations, neurotensin binding displays positive cooperativity with

80 We purified three neurotensin-bound NTR1 variants from Escherichia coli an

81 lar [Ca(2+)] induced by GPCR agonists (e.g., neurotensin, bradykinin, and angiotensin II).

82 siologically important neuropeptides such as neurotensin, bradykinin, and gonadotropin-releasing horm

83 tors were treated with fluorescently labeled neurotensin (BT-NT).

84 ed in most of the pharmacological effects of neurotensin but is associated with hypothermia and hypot

85 ACE2 can also cleave des-Arg bradykinin and neurotensin but not bradykinin or 15 other vasoactive an

86 In the lateral hypothalamus, neurotensin, but neither orexin nor MCH neurons, express

87 have discovered that the modulatory peptide neurotensin can induce a persistent synaptic depression

88 Exposure of colonic explants to toxin A or neurotensin causes mast cell degranulation, which is inh

89 Intra-PFC administration of neurotensin concentration-dependently increased extracel

90 el biochemical species (human serum albumin, neurotensin, creatinine, glycine, and alanine) were reta

91 Tissue concentrations of CCK, GIP, and neurotensin decline with feeding.

92 Neurotensin decreases food intake in the rat when inject

93 rine genes: prohormone convertase 1 (PCSK1); neurotensin; delta/notch-like EGF repeat containing; and

94 with 5 mg/kg morphine (intraperitonally) or neurotensin directly into the periaqueductal gray region

95 Since neurotensin-dopamine interactions have been implicated i

96 ptor dynamics, possibly explains the reduced neurotensin efficacy in the constitutively active NTSR1

97 Neurotensin exerts potent analgesia by acting at both NT

98 Neurotensin expression increased colony formation by HCT

99 Striatal tissue concentrations of neurotensin, expression of neurotensin/neuromedin N (NT/

100 n-G shows a high degree of similarity to the neurotensin family of peptides.

101 ing gastrin-releasing peptide, neuromedin B, neurotensin, gastrin, cholecystokinin and arginine vasop

102 se, including substance P, somatostatin, and neurotensin have actions such that they should be consid

103 The neurotensin hexapapetide fragment NT(8-13) is a potent a

104 sin/neuromedin N (NT/N) mRNA, and numbers of neurotensin-immunoreactive neurons are increased by d-am

105 The GABA- and neurotensin-immunoreactive neurons project to the SCN wi

106 ting less than 50 amol of angiotensin II and neurotensin in a microLC MALDI MS run under standard exp

107 ntal approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsych

108 NTS1 and behaves like the endogenous ligand neurotensin in the functional assay.

109 astrointestinal tract, suggesting a role for neurotensin in the interrelationships that comprise the

110 , these findings suggest a selective role of neurotensin in the modulation of dopamine neurotransmiss

111 high-affinity neurotensin receptor (NTR) and neurotensin in these subdivisions of rat NAc to determin

112 For triply charged neurotensin, in which a direct comparison can be made be

113 insulinotropic peptide (GIP), glucagon, and neurotensin increase by respective factors of 25-, 6-, 6

114 In mice, intraperitoneal administration of neurotensin increased the growth rate of HCT-116 xenogra

115 Cell stimulation with the GPCR agonist neurotensin induced a rapid and reversible plasma membra

116 asphyxial cardiac arrest was decreased with neurotensin-induced hypothermia (14+/-11 secs) and prolo

117 There was less ischemic neuronal damage with neurotensin-induced hypothermia (28+/-24%) and prolonged

118 fter asphyxial cardiac arrest was lower with neurotensin-induced hypothermia (score, 0) and prolonged

119 or 24 hrs (prolonged external cooling) or by neurotensin-induced hypothermia administration 30 mins a

120 Neurotensin-induced hypothermia improved neurologic outc

121 s were randomized to a normothermic control, neurotensin-induced hypothermia, brief external cooling,

122 Our results show that neurotensin-induced mast cell degranulation in colonic e

123 examined whether substance P is involved in neurotensin-induced mast cell degranulation.

124 Whereas CPA6 converts enkephalin and neurotensin into forms known to be inactive toward their

125 Administration of neurotensin into the brain results in responses in the g

126 that colonic mast activation in response to neurotensin involves release of substance P.

127 Neurotensin is a tridecapeptide present in the brain and

128 Neurotensin is a tridecapeptide that participates in reg

129 Nearly all neurotensin is colocalized with neuropeptide Y in IGL ne

130 In the rat prefrontal cortex (PFC), neurotensin is exclusively localized to dopamine axons a

131 Because neurotensin is exclusively localized to dopamine axons i

132 The estimated IC(50) value (2 nM) for neurotensin is in agreement with the literature; this ag

133 alpha)q/11 upon treatment of SCLC cells with neurotensin is not inhibited by ET-18-OCH3.

134 Neurotensin is present in selective mesolimbic dopaminer

135 on striatal, nigral, cortical, and accumbens neurotensin-like immunoreactivity (NTLI); (2) the effect

136 minergic behavioral effects of basal ganglia neurotensin may be attenuated in conditions of reduced d

137 The peptide transmitter neurotensin may be one such modulator of interneurons.

138 The neuropeptide neurotensin mediates several intestinal functions, inclu

139 Neurotensin MPN, orexin-containing LHA, and catecholamin

140 RH) neurons show extensive coexpression with neurotensin mRNA, but they are distinct from hypocretin/

141 os-IR was observed in neurons that expressed neurotensin mRNA.

142 tide Y and decreased proopiomelanocortin and neurotensin mRNAs in the arcuate nucleus (ARH); increase

143 ular nucleus (PVH) and (2) increased CRH and neurotensin mRNAs in the lateral hypothalamic (LHA) and

144 Expression of the neurotensin/neuromedin (NT/N) gene in preoptic area neur

145 Expression of the gene encoding neurotensin/neuromedin N (NT/N) is mostly limited to the

146 concentrations of neurotensin, expression of neurotensin/neuromedin N (NT/N) mRNA, and numbers of neu

147 her, these observations suggest that CRH and neurotensin neurons in the LHA constitute a novel anatom

148 Specific loss of SCN neurotensin neurons was associated with loss of activity

149 Some thyrotropin-releasing hormone and neurotensin neurons were labeled, but none of the calcit

150 es-specific vasopressin and species-specific neurotensin neurons.

151 It was previously shown that bombesin and/or neurotensin (NT) acts as a survival and migratory factor

152 Expression of the neuropeptide neurotensin (NT) and its high affinity receptor (NTR1) i

153 The expression of neurotensin (NT) and its receptor (NTR1) is up-regulated

154 The peptides neurotensin (NT) and neuromedin N exert effects on neuro

155 Neurotensin (NT) and neurotensin receptor 1 (NTR1) have

156 The peptide transmitter neurotensin (NT) exerts diverse neurochemical effects th

157 A method was developed to quantify neurotensin (NT) fragment [8-13] and a novel NT[8-13] de

158 minal end of the minimal biologically active neurotensin (NT) fragment, leading to the synthesis of n

159 Release of neurotensin (NT) from intestines is markedly stimulated

160 ral injections of leptin induce hypothalamic neurotensin (NT) gene expression in association with a r

161 Neurotensin (NT) has emerged as an important modulator o

162 zine, increase synthesis of the neuropeptide neurotensin (NT) in both the striatum and the nucleus ac

163 eported elevated serum levels of the peptide neurotensin (NT) in children with autism spectrum disord

164 (PMA)-mediated secretion of the gut peptide neurotensin (NT) in the BON human endocrine cell line.

165 ANC-1 as a model system, we demonstrate that neurotensin (NT) induced a rapid and striking activation

166 ANC-1 as a model system, we demonstrate that neurotensin (NT) induced translocation of phosphorylated

167 Neurotensin (NT) is a 13 amino acid neuropeptide that is

168 Neurotensin (NT) is a 13-amino-acid peptide that, among

169 Neurotensin (NT) is a gastrointestinal neuropeptide that

170 Neurotensin (NT) is a gut peptide that plays an importan

171 Neurotensin (NT) is a gut peptide that plays an importan

172 Neurotensin (NT) is a neuropeptide neurotransmitter in t

173 Neurotensin (NT) is a neuropeptide with antinociceptive

174 Neurotensin (NT) is a tridecapeptide neurotransmitter in

175 Native neurotensin (NT) is a tridecapeptide that binds to NTR a

176 The neuropeptide/hormone neurotensin (NT) mediates intestinal inflammation and ce

177 Neurotensin (NT) modulates ventral tegmental area (VTA)

178 In the Arc, a few CART neurons coexpress neurotensin (NT) mRNA.

179 acid (PNA) complementary to mRNA of the rat neurotensin (NT) receptor (NTR1) was demonstrated by a g

180 transduction properties of the class A GPCR neurotensin (NT) receptor 1 (NTS1) under defined experim

181 In contrast to these receptors, the neurotensin (NT) receptor NTS1 is much less stable in de

182 The neurotensin (NT) receptor-1 (NTS1) is overexpressed in a

183 Previous studies indicated that the peptide neurotensin (NT) stimulates Cl(-) secretion in animal sm

184 Application of the modulatory peptide neurotensin (NT) to midbrain dopaminergic neurons transi

185 Neurotensin (NT) triggers signaling in human colonic epi

186 Neurotensin (NT) via its receptor 1 (NTR1) modulates the

187 eleasing hormone (CRH), enkephalin (ENK), or neurotensin (NT) with glutamic acid decarboxylase isofor

188 Neurotensin (NT), a neuropeptide released in the gastroi

189 (CALR), gastrin releasing peptide (GRP), and neurotensin (NT), and receive input from the retina and

190 the present study, we identify the effect of neurotensin (NT), one of the most abundant peptides in t

191 own to be secreted by NE-like cells, such as neurotensin (NT), parathyroid hormone-related peptide, s

192 ng corticotropin-releasing hormone (CRH) and neurotensin (NT), secreted in response to the metabolic

193 nd methamphetamine) on neuropeptides such as neurotensin (NT), the present study was designed to dete

194 that focus on receptors for the neuropeptide neurotensin (NT).

195 ts effect being nearly comparable to that of neurotensin (NT).

196 Neurotensin (NT; also known as NTS), a 13-amino-acid pep

197 ed peptides containing the sequence of human neurotensin, NT4, are much more selective than native mo

198 ecific binding of ligands, arrays presenting neurotensin (NTR1), adrenergic (beta1), and dopamine (D1

199 abinoid (CB(1)) antagonist (SR141716), and a neurotensin (NTS(1)) antagonist (SR48692).

200 es of the IL-8 functional network identified neurotensin (NTS) and CXCL1 to be preferentially express

201 Neurotensin (NTS) is a 13 amino acid neuropeptide that i

202 Neurotensin (NTS) is a 13-amino-acid peptide that functi

203 c LHA leptin receptor (LepRb)-containing and neurotensin (Nts)-containing (LepRb(Nts)) neurons lie in

204 e we identify a steroid-responsive subset of neurotensin (Nts)-expressing mPOA neurons that interface

205 of bivalent ligands for dopamine D2 receptor/neurotensin NTS1 receptor (D2R/NTS1R) heterodimers.

206 However, the effects of neurotensin on cortical interneurons are poorly understo

207 itive binding assay with BT-NT and unlabeled neurotensin on NTR1 arrays.

208 and downstream signaling, whether induced by neurotensin or ionizing radiation, establish a molecular

209 2-adrenergic compounds, but not cannabinoid, neurotensin, or muscarinic drugs.

210 Thiolated neurotensin peptide (Cys-NT) efficiently reacted with (1

211 nd to specifically target pancreatic cancer, neurotensin peptide (NT)-conjugated polyethylene glycol

212 Thiolated neurotensin peptide was then labeled with (18)F using th

213 a simple and efficient method to radiolabel neurotensin peptide with (18)F for NTR-targeted imaging.

214 We conclude that neurotensin plays a key role in the pathogenesis of C. d

215 axons in the PFC, we also determined whether neurotensin plays a role in the ability of dopamine agon

216 These findings suggest that neurotensin plays an important role in regulating prefro

217 releasing hormone, galanin, neuropeptide Y, neurotensin, preproenkephalin and tachykinin 1; this inv

218 Neurotensin promotes inflammation and colon cancer via t

219 These results suggest that central neurotensin protects the gastric mucosa against CWR-indu

220 roscopic immunolabeling of the high-affinity neurotensin receptor (NTR) and neurotensin in these subd

221 The prevalence of neurotensin receptor (NTR) in several human tumors makes

222 To date, there are two types of the neurotensin receptor (NTR) that have been molecularly cl

223 1AR), endothelin type A receptor (ETAR), and neurotensin receptor (NTR).

224 e promoter region of the mouse high affinity neurotensin receptor (Ntr-1) gene was characterized, and

225 The type 1 neurotensin receptor (NTS1) belongs to the G protein-cou

226 re of a constitutively active, agonist-bound neurotensin receptor (NTSR1) and molecular dynamics simu

227 groups were inherently detrimental to human neurotensin receptor 1 (hNTR1) binding affinity or recep

228 peutic efficacy of oAd/DCN/LRP-PEG-NT toward neurotensin receptor 1 (NTR)-overexpressing pancreatic c

229 cally induced hypothermia (PIH) by the novel neurotensin receptor 1 (NTR1) agonist ABS-201 in a focal

230 mbinations that preferentially interact with neurotensin receptor 1 (NTR1) and our stabilized mutants

231 2-carboxylic acid (SR48692), a high-affinity neurotensin receptor 1 (NTR1) antagonist.

232 Using neurotensin receptor 1 (NTR1) as a proof of principle, w

233 In this study, we define the high-affinity neurotensin receptor 1 (NTR1) as a tractable new molecul

234 Increased expression of neurotensin receptor 1 (NTR1) has been shown in a large

235 Neurotensin (NT) and neurotensin receptor 1 (NTR1) have been shown to play a

236 Neurotensin receptor 1 (NTR1) is overexpressed in ductal

237 tivating the G protein-coupled receptor, the neurotensin receptor 1 (NTR1).

238 quired for this network disturbance, we used neurotensin receptor 1 (Ntsr1) cre-driver mice to ablate

239 STR1, SSTR2), kisspeptin recepotor (KissR1), neurotensin receptor 1 (NTSR1), neuropeptide S receptor

240 ese effects requires mast cell expression of neurotensin receptor 1 and neurolysin.

241 Starting from the rat neurotensin receptor 1, a class A GPCR, we generated a s

242 receptors (angiotensin II type 1A receptor, neurotensin receptor 1, vasopressin V2 receptor, thyrotr

243 Pharmacological manipulation of neurotensin receptor 2 confirms behavioural effects obse

244 acrophage inflammatory protein 1 (MIP-1) and neurotensin receptor 2.

245 te as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy

246 ta further support a role for NT69L or other neurotensin receptor agonists to treat nicotine addictio

247 eadministration of a mu opioid receptor or a neurotensin receptor antagonist into the ventral PAG.

248 Pretreatment of rats with the neurotensin receptor antagonist SR-48, 692 inhibits toxi

249 administered peripherally, serum levels and neurotensin receptor binding potency of 1 peaked within

250 l and hydrodynamic experiments that purified neurotensin receptor NTS1, a class A GPCR, dimerizes in

251 We previously determined the structure of neurotensin receptor NTSR1 in an active-like conformatio

252 and a hormone through the activation of the neurotensin receptor NTSR1, a G-protein-coupled receptor

253 (AS-MOR MM), antisense PNAs targeted to the neurotensin receptor subtype 1 (AS-NTR1), or saline and

254 in-G were found to be potent agonists of rat neurotensin receptor type 1.

255 Compounds acting via the neurotensin receptor type 2 (NTS2) are known to be activ

256 cosylated Thr10 contulakin-G for a number of neurotensin receptor types including the human neurotens

257 Neurotensin receptor was expressed in 88% of the surgica

258 of the GHS-R is most closely related to the neurotensin receptor-1 (NT-R1) (35% overall protein iden

259 Neurotensin receptor-1 (NTR1) is a promising target for

260 on by binding of its high affinity receptor, neurotensin receptor-1 (NTR1).

261 ding only to microspots corresponding to the neurotensin receptor; this specificity was further demon

262 Accumulating evidence suggests that neurotensin receptors (NTRs) play key roles in cancer gr

263 Compounds active at neurotensin receptors (NTS1 and NTS2) exert analgesic ef

264 Compound 1 binds to human neurotensin receptors 1 and 2 with IC(50) of 10.6 and 54

265 tained high affinity and agonist potency for neurotensin receptors and exhibited dramatically improve

266 wo new tritiated tracers for angiotensin and neurotensin receptors are described.

267 Ca2+ mobilization mediated by neurotensin receptors is also inhibited by ET-18-OCH3.

268 ither the protein phosphatase calcineurin or neurotensin receptors, and persists surprisingly long af

269 opeptide growth factor, and its two specific neurotensin receptors, NTSR1 and NTSR2, were shown to be

270 pitates with G(alpha)q/11 upon activation of neurotensin receptors; this association is inhibited by

271 Targets of neurotensin-regulated microRNAs were identified via bioi

272 Neurotensin regulates both satiety and breast cancer gro

273 ysis in freely moving rats to assess whether neurotensin regulates PFC GABAergic interneurons.

274 Xenin-25 is a 25-amino acid neurotensin-related peptide that amplifies GIP-mediated

275 ating that D2 autoreceptor agonists increase neurotensin release from dopamine-neurotensin axons in t

276 ption that is mediated in part by opioid and neurotensin release within the ventral PAG.

277 Peptide YY (PYY) and neurotensin responses resembled those of GLP-1.

278 Unlike neurotensin responses, ibogaine alone did not alter DYN

279 Neurotensin's effects are mediated mainly through two re

280 Systematic modification of neurotensin sequence in NT4 peptides led to identificati

281 nolase, parathyroid hormone-related peptide, neurotensin, serotonin, and chromogranin A.

282 n digesting pythons, the regulatory peptides neurotensin, somatostatin, motilin, and vasoactive intes

283 Neurotensin stimulated differential expression of 38 mic

284 ed microarray analysis of mRNA expression by neurotensin-stimulated NCM460 cells that overexpressed N

285 opin-releasing hormone, nerve growth factor, neurotensin, substance P and mast cells are recruited hi

286 Larger peptides such as neurotensin, substance P, bradykinin, and the oxidized i

287 Because ibogaine influences the activity of neurotensin systems, a dopamine-linked neuropeptide, the

288 The ability of neurotensin to increase GABA levels in the PFC was also

289 heir stress resistance and the adsorption of neurotensin to plasma membranes with the distinct biphas

290 ding of NT4 peptides, with respect to native neurotensin, to either cancer cell lines or human cancer

291 neurotensin type 1 receptor (hNTR1), the rat neurotensin type 1 and type 2 receptors, and the mouse n

292 urotensin receptor types including the human neurotensin type 1 receptor (hNTR1), the rat neurotensin

293 n (group I glutamate metabotropic receptors, neurotensin type 1) could similarly elicit wave-like act

294 n type 1 and type 2 receptors, and the mouse neurotensin type 3 receptor were determined.

295 natriuretic peptide, somatostatin, oxytocin, neurotensin, vasopressin, and substance P), and three th

296 In each region, neurotensin was detected in a few NTR-immunoreactive axo

297 Neurotensin was functional in B cell lines; it induced t

298 TSR2 was overexpressed, NTSR1 decreased, and neurotensin was unexpressed in B cell leukemia patient's

299 -dead TrkA, and siRNA against TrkA sortilin, neurotensin, whereas siRNA against p75(NTR) and the MAP

300 eptor concentrations, NTS1 binds the agonist neurotensin with a Hill slope of approximately 1; at hig